Neuron-associated macrophage proliferation in the sensory ganglia is associated with peripheral nerve injury-induced neuropathic pain involving CX3CR1 signaling

Abstract

Resident macrophages are distributed across all tissues and are highly heterogeneous due to adaptation to different tissue-specific environments. The resident macrophages of the sensory ganglia (sensory neuron-associated macrophages, sNAMs) are in close contact with the cell body of primary sensory neurons and might play physiological and pathophysiological roles. After peripheral nerve injury, there is an increase in the population of macrophage in the sensory ganglia, which have been implicated in different conditions, including neuropathic pain development. However, it is still under debate whether macrophage accumulation in the sensory ganglia after peripheral nerve injury is due to the local proliferation of resident macrophages or a result of blood monocyte infiltration. Here, we confirmed that the number of macrophages increased in the sensory ganglia after the spared nerve injury (SNI) model in mice. Using different approaches, we found that the increase in the number of macrophages in the sensory ganglia after SNI is a consequence of the proliferation of resident CX3CR1+ macrophages, which participate in the development of neuropathic pain, but not due to infiltration of peripheral blood monocytes. These proliferating macrophages are the source of pro-inflammatory cytokines such as TNF and IL-1b. In addition, we found that CX3CR1 signaling is involved in the sNAMs proliferation and neuropathic pain development after peripheral nerve injury. In summary, these results indicated that peripheral nerve injury leads to sNAMs proliferation in the sensory ganglia in a CX3CR1-dependent manner accounting for neuropathic pain development. In conclusion, sNAMs proliferation could be modulated to change pathophysiological conditions such as chronic neuropathic pain.

Data availability

All data generated or analyzed during this study are included in the manuscript. Public scRNA-seq data are available in Gene Expression Omnibus (GEO) database under the series number GSE139103 (Avraham et al. 2020).

The following previously published data sets were used

Article and author information

Author details

  1. Rafaela Mano Guimarães

    Department of Pharmacology, University of Sao Paulo, Ribeirao Preto, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  2. Conceição Elidianne Aníbal-Silva

    Department of Pharmacology, University of Sao Paulo, Ribeirão Preto, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  3. Marcela Davoli-Ferreira

    Department of Pharmacology, University of Sao Paulo, Ribeirao Preto, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  4. Francisco Isaac Fernandes Gomes

    Department of Pharmacology, University of Sao Paulo, Ribeirao Preto, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  5. Atlante Silva Mendes

    Department of Pharmacology, University of Sao Paulo, Ribeirao Preto, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  6. Maria Claudia Magalhães Cavallini

    Department of Pharmacology, University of Sao Paulo, Ribeirão Preto, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  7. Miriam Mendes Fonseca

    Department of Pharmacology, University of Sao Paulo, Ribeirao Preto, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  8. Samara Damasceno

    Department of Pharmacology, University of Sao Paulo, Ribeirao Preto, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  9. Larissa Pinto Andrade

    Department of Pharmacology, University of Sao Paulo, Ribeirao Preto, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  10. Marco Colonna

    Department of Pathology and Immunology, Washington University in St. Louis, Saint Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Cyril Rivat

    Institut des Neurosciences de Montpellier, Université de Montpellier, Montpellier, France
    Competing interests
    The authors declare that no competing interests exist.
  12. Fernando Q Cunha

    Department of Pharmacology, University of Sao Paulo, Ribeirão Preto, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  13. José C Alves-Filho

    Department of Pharmacology, University of Sao Paulo, Ribeirao Preto, Brazil
    Competing interests
    The authors declare that no competing interests exist.
  14. Thiago Mattar Cunha

    Department of Pharmacology, University of Sao Paulo, Ribeirao Preto, Brazil
    For correspondence
    thicunha@fmrp.usp.br
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1084-0065

Funding

The authors declare that there was no funding for this work.

Ethics

Animal experimentation: Animal care and handling procedures were under the guidelines of the International Association for the Study of Pain for those animals used in pain research and were approved by the Committee for Ethics in Animal Research of the Ribeirao Preto Medical School- University of São Paulo (Process number 002/2017).

Copyright

© 2023, Guimarães et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,780
    views
  • 459
    downloads
  • 22
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Rafaela Mano Guimarães
  2. Conceição Elidianne Aníbal-Silva
  3. Marcela Davoli-Ferreira
  4. Francisco Isaac Fernandes Gomes
  5. Atlante Silva Mendes
  6. Maria Claudia Magalhães Cavallini
  7. Miriam Mendes Fonseca
  8. Samara Damasceno
  9. Larissa Pinto Andrade
  10. Marco Colonna
  11. Cyril Rivat
  12. Fernando Q Cunha
  13. José C Alves-Filho
  14. Thiago Mattar Cunha
(2023)
Neuron-associated macrophage proliferation in the sensory ganglia is associated with peripheral nerve injury-induced neuropathic pain involving CX3CR1 signaling
eLife 12:e78515.
https://doi.org/10.7554/eLife.78515

Share this article

https://doi.org/10.7554/eLife.78515

Further reading

    1. Immunology and Inflammation
    Shih-Wen Huang, Yein-Gei Lai ... Nan-Shih Liao
    Research Article

    Natural killer (NK) cells can control metastasis through cytotoxicity and IFN-γ production independently of T cells in experimental metastasis mouse models. The inverse correlation between NK activity and metastasis incidence supports a critical role for NK cells in human metastatic surveillance. However, autologous NK cell therapy has shown limited benefit in treating patients with metastatic solid tumors. Using a spontaneous metastasis mouse model of MHC-I+ breast cancer, we found that transfer of IL-15/IL-12-conditioned syngeneic NK cells after primary tumor resection promoted long-term survival of mice with low metastatic burden and induced a tumor-specific protective T cell response that is essential for the therapeutic effect. Furthermore, NK cell transfer augments activation of conventional dendritic cells (cDCs), Foxp3-CD4+ T cells and stem cell-like CD8+ T cells in metastatic lungs, to which IFN-γ of the transferred NK cells contributes significantly. These results imply direct interactions between transferred NK cells and endogenous cDCs to enhance T cell activation. We conducted an investigator-initiated clinical trial of autologous NK cell therapy in six patients with advanced cancer and observed that the NK cell therapy was safe and showed signs of effectiveness. These findings indicate that autologous NK cell therapy is effective in treating established low burden metastases of MHC-I+ tumor cells by activating the cDC-T cell axis at metastatic sites.

    1. Genetics and Genomics
    2. Immunology and Inflammation
    Patsy R Tomlinson, Rachel G Knox ... Robert K Semple
    Research Article

    PIK3R1 encodes three regulatory subunits of class IA phosphoinositide 3-kinase (PI3K), each associating with any of three catalytic subunits, namely p110α, p110β, or p110δ. Constitutional PIK3R1 mutations cause diseases with a genotype-phenotype relationship not yet fully explained: heterozygous loss-of-function mutations cause SHORT syndrome, featuring insulin resistance and short stature attributed to reduced p110α function, while heterozygous activating mutations cause immunodeficiency, attributed to p110δ activation and known as APDS2. Surprisingly, APDS2 patients do not show features of p110α hyperactivation, but do commonly have SHORT syndrome-like features, suggesting p110α hypofunction. We sought to investigate this. In dermal fibroblasts from an APDS2 patient, we found no increased PI3K signalling, with p110δ expression markedly reduced. In preadipocytes, the APDS2 variant was potently dominant negative, associating with Irs1 and Irs2 but failing to heterodimerise with p110α. This attenuation of p110α signalling by a p110δ-activating PIK3R1 variant potentially explains co-incidence of gain-of-function and loss-of-function PIK3R1 phenotypes.